Evidence map›Paper›PMID 39372951›Full record

ArticleFrontiers in cell and developmental biology2024

YTHDF3 modulates the progression of breast cancer cells by regulating FGF2 through m

R F Gong, Z H Zhang, T T Sun, Y X Zhao, Wen Fang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

R F Gong *Center for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Z H Zhang *School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, China.
T T SunThe Affiliated Cancer Hospital of Guizhou Medical University, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Y X ZhaoSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang, China.
Wen FangCenter for Clinical Laboratories, The Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Breast cancer (BC) is a prevailing malignancy among women, and its inconspicuous development contributes significantly to mortality. The RNA N6-methyladenosine (m Methods: The expression of YTHDF3 in both cell lines and patient tissues was examined using Western blotting, reverse transcription quantitative PCR (RT-qPCR), and immunohistochemistry (IHC) techniques. Bioinformatics analysis of methylated RNA immunoprecipitation sequencing (MeRIP-seq) and transcriptome RNA sequencing (RNA-seq) data was employed to screen for the target genes of YTHDF3. The main focus of this study was to investigate the Results: By constructing a risk model using the TCGA database, YTHDF3 was identified as a high-risk factor among m Conclusions: In summary, our study elucidates the role of YTHDF3 as an oncogene in maintaining FGF2 expression in BC cells through an m

Indexed as

breast canerepigeneticsFGF2N6-methyladenosineYTHDF3

Identifiers

PMID39372951
PMCPMC11449838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.